Pacific Biosciences of California Inc reports results for the quarter ended in September - Earnings Summary

Pacific Biosciences of California

07/11/2022 22:05

* Pacific Biosciences of California Inc  PACB.OQ  reported a
quarterly adjusted loss of 34 cents​​ per share for the quarter
ended in September. The mean expectation of six analysts for the
quarter was for a loss of 33 cents per share.
    * Revenue fell 7.4% to $32.31 million from a year ago;
analysts
expected $35.40 million. 
    * Pacific Biosciences of California Inc's reported EPS for
the
quarter was a loss of 34 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Pacific Biosciences of California Inc shares had risen
by 42.1%
this quarter and lost 59.7% so far this year.
    * The company reported a quarterly loss of $76.97 million.
    * Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:05 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.33          -0.34          Missed
 Jun. 30 2022      -0.32          -0.32          Met
 Mar. 31 2022      -0.31          -0.37          Missed
 Dec. 31 2021      -0.28          -0.31          Missed